Federal Circuit Rules for Merck in Patent Dispute with Teva

Law360, New York (October 31, 2003, 12:00 AM EST) -- The United States Court of Appeals for the Federal Circuit ruled in favor of pharmaceutical company Merck in a patent dispute with Israeli generics maker Teva Pharmaceutical Industries over Merck's Fosamax® tablets.

In a two to one decision, the three-judge panel affirmed the decision of the Federal District Court for Delaware that Merck & Co.’s patent covering the use of sodium alendronate was valid; that the patent term extension was proper; and that Teva’s proposed alendronate formulations would infringe Merck’s patent.

Fosamax is used for the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.